Shields Radiology Associates — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$10,310	7
2023	Research	$20,865	13
2022	Research	$10,860	4
2021	Research	$40,674	22
2019	Research	$85,130	19

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $75,775 9 payments
Daiichi Sankyo Inc. $30,734 18 payments
EMD Serono, Inc. $24,605 7 payments
Merck KGaA $22,215 16 payments
AstraZeneca UK Limited $8,960 4 payments
H. Lundbeck A S $5,550 11 payments

Studies the money was for Research payments · program years 2019–2025

M13-813 $75,775 9 payments
Ds1001-A-J101 $30,734 18 payments
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) $17,550 7 payments
A Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy (INSIGHT 2 Study). $10,860 4 payments
A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus platinum doublet as a first line treatment of recurrent or Stage IV PD-L1+ non small cell lung cancer $7,545 2 payments
A Phase II Study Assessing the Efficacy of Osimertinib in Combination with Savolitinib in Patients with EGFRm+ and MET+ Locally Advanced or Metastatic Non-Small Cell Lung Cancer who have Progressed Following Treatment with Osimertinib $6,845 2 payments
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) $6,200 1 payment
Interventional, randomized, double-blind, placebo-controlled, single-ascending-dose study investigating the safety, tolerability, and pharmacokinetic properties of Lu AF87908 in healthy subjects and patients with Alzheimers disease $4,725 7 payments
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) $3,315 6 payments
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON) $1,600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.